Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | TEC | P42680 | 1/20 | 0.35 |
| ▸ | TXK | P42681 | 1/20 | 0.35 |
| ▸ | BMX | P51813 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715431 | 1.00 | SYK (0.40) | SYKEGFRBTKJAK2LYN | |
| SCHEMBL2718804 | 0.90 | SYK (0.42) | SYKEGFRBTKJAK2LYN | |
| SCHEMBL2715377 | 0.90 | SYK (0.42) | SYKEGFRBTKJAK2LYN | |
| SCHEMBL2715849 | 0.88 | PIK3CA (0.38) | SYK | |
| SCHEMBL2716094 | 0.86 | EGFR (0.38) | SYKEGFRITK | |
| SCHEMBL2718568 | 0.85 | SYK (0.41) | SYK | |
| SCHEMBL2715948 | 0.83 | SYK (0.46) | SYKBTK | |
| SCHEMBL2715944 | 0.83 | SYK (0.46) | SYKBTK | |
| SCHEMBL2719062 | 0.82 | GAA (0.44) | SYKJAK2 | |
| SCHEMBL2717572 | 0.81 | EGFR (0.38) | SYKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012061415-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |